Oncology Drugs
694 FDA-approved drugs
TheraRadar tracks 694 FDA-approved oncology drugs from 278 companies across 70 drug classes, led by Pfizer, with 22,092 active clinical trials in the pipeline. Explore recent approvals, top companies, active trials by indication, and drug classes for Oncology.
Oncology Approvals by Year
23
'15
14
'16
27
'17
34
'18
25
'19
35
'20
26
'21
27
'22
32
'23
33
'24
53
'25
10
'26
Recent Oncology Drug Approvals
BOSUTINIB
BOSUTINIB MONOHYDRATE
2026-06-12
MSN
VENETOCLAX
VENETOCLAX
2026-05-15
Dr. Reddy's
VEPPANU
VEPDEGESTRANT
adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negativ...
2026-05-01
ARVINAS OPERATIONS
LIFYORLI (COPACKAGED)
RELACORILANT
LIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-r...
2026-03-25
CORCEPT THERAP
LOARGYS
PEGZILARGINASE-NBLN
hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency...
2026-02-23
IMMEDICA PHARMA AB
FAVLYXA
FLUOROURACIL
INDICATIONS AND USAGE Fluorouracil Cream is recommended for the topical treatment of multiple actini...
2026-02-20
AVYXA HOLDINGS
IDELALISIB
IDELALISIB
patients with: Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patien...
2026-02-17
NATCO
PI3K
AVOPEF
ETOPOSIDE
refractory testicular cancer in adult patients...
2026-02-13
AVYXA HOLDINGS
VYKOURA
LEUCOVORIN CALCIUM
pernicious anemia and megaloblastic anemia secondary to lack of vitamin B 12 , because of the risk o...
2026-02-03
AVYXA HOLDINGS
FILKRI
FILGRASTIM-LAHA
2026-01-15
ACCORD BIOPHARMA INC.
OZILTUS
DENOSUMAB-MOBZ
adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where...
2025-12-19
AMNEAL PHARMS
BONCRESA
DENOSUMAB-MOBZ
postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporot...
2025-12-19
AMNEAL PHARMS
RYBREVANT FASPRO
AMIVANTAMAB AND HYALURONIDASE-LPUJ
adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858...
2025-12-17
Johnson & Johnson
EGFRMET
NILOTINIB
NILOTINIB
2025-12-15
TORRENT
ARMLUPEG
PEGFILGRASTIM-UNNE
the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation...
2025-11-28
Lupin
NILOTINIB HYDROCHLORIDE DIHYDRATE
NILOTINIB HYDROCHLORIDE DIHYDRATE
2025-11-19
HETERO LABS LTD V
HYRNUO
SEVABERTINIB
adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) w...
2025-11-19
Bayer
HER2EGFR
POHERDY
PERTUZUMAB-DPZB
2025-11-13
SHANGHAI HENLIUS BIOTECH
KOMZIFTI
ZIFTOMENIB
adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible nucleopho...
2025-11-13
KURA
AXITINIB
AXITINIB
2025-10-30
Novartis
Showing the 20 most recent of 694 oncology drugs. View all 694 →
Top Oncology Companies
Oncology Active Trials by Indication
22,092 active trials — the forward pipeline, not just approvals.
Solid Tumor (Advanced) 3,521 Non-Hodgkin Lymphoma 1,626 Breast Cancer 1,516 NSCLC 1,467 Colorectal Cancer 1,146 Prostate Cancer 879 AML 703 Multiple Myeloma 678
All competitive landscapes → Oncology Drug Classes
Kinase Inhibitor 43
Alkylating Drug 18
RANK Ligand Inhibitor 17
Leukocyte Growth Factor 17
Nucleoside Metabolic Inhibitor 15
Programmed Death Receptor-1 Blocking Antibody 9
HER2/neu Receptor Antagonist 8
Endoglycosidase 6
Vascular Endothelial Growth Factor Inhibitor 6
Retinoid 6
Oncology at a Glance
- Total Drugs
- 694
- Companies
- 278
- Drug Classes
- 70
- Active Trials
- 22,092
- Latest Approval
- 2026-06-12